• HOME
  • WORKFLOW
  • REPORT
  • PUBLICATIONS
  • CONFERENCES
  • TEAM
  • CONTACT

HEPATIQ REPORT

The HEPATIQ physician report includes color-coded serial and differential graphs and an interpretation of the quantitative indices. A sample report is shown below for illustration.
  • The HEPATIQ report provides six quantitative indices used for diagnosis, staging, interventions, and monitoring liver disease progression.
  • PHM - Quantitative Liver Function (normal ≥100).  Patients with PHM < 95 have cirrhosis and an almost 15-fold increase in the risk of clinical outcomes such as ascites, variceal bleeding, hepatic encephalopathy, and death.
  • fLV – Liver Volume (7 ≤ normal < 12).  This index together with PHM can be used to differentially diagnose fatty liver, steatohepatitis and cirrhosis.
  • fSV - Spleen Volume (>0 normal < 2.5).  This index together with PHM can be used to differentially diagnose portal hypertension, infiltrative spleen disease and cirrhosis.  
  • HAI - Activity Index (normal > -0.1).  This index captures the effect of alcoholic activity and may be used to diagnose alcoholic hepatitis and distinguish ASH and NASH.  
  • eFS - Fibrosis Score (normal = 0, range 0 to 6).  This categorical index of liver fibrosis correlates with the Ishak fibrosis score.
  • eEV - Esophageal Varices (normal =0, range 0 to 3).  This categorical index estimates presence and size of esophageal varices and the risk of bleeding.
The HEPATIQ indices have myriad uses:
  • Decompensation: For patients with severe fibrosis or cirrhosis, PHM and fSV indicate likelihood of liver decompensation (outcomes such as ascites, varices, encephalopathy, etc.). 
  • Portal Hypertension: fSV provides a simple non-invasive indication of portal hypertension.  May be useful for assessing a transjugular intrahepatic portosystemic shunt (TIPS).
  • Hemodynamics: PHM and fLV indicate intrahepatic hemodynamic conditions allowing differentiation of acute and chronic liver disease. 
  • Steatohepatitis: HAI and fLV allow differentiation of alcoholic steatohepatitis (ASH) and nonalcoholic steatohepatitis (NASH). 
  • Interventions: For HCC patients being considered for radioembolization or chemotherapy, PHM indicates likelihood of post-intervention liver failure.
  • Transplantation: For patients with severe liver disease but MELD score not high enough for transplant priority, low PHM may be used to justify a MELD exception. 
  • Therapy: PHM provides an objective assessment of the efficacy of pharmacological, radiological or surgical therapies for the underlying causes of liver disease. 
home
WORKFLOW
REPORT
PUBLICATIONS
CONFERENCES
TEAM
CONTACT

HEPATIQ Free Trial

For a free trial of HEPATIQ at your institution, please submit:

Thank you!

We have received your submission.

Error

Bad respond
Contact: sales@hepatiq.com
Hepatiq, Inc. 9 Corporate Park, Suite 130 Irvine, CA 92606, USA. www.hepatiq.com
HEPATIQ®, PHM®, fLV®, fSV®, HAI®, eFS®, eEV®, QLSS® and TRUPAS® are all trademarks of Hepatiq, Inc. The HEPATIQ software is protected by several US and foreign patents.
Copyright © 2023 Hepatiq, Inc. All rights reserved.

We use cookies to enable essential functionality on our website, and analyze website traffic. By clicking Accept you consent to our use of cookies. Read about how we use cookies.

Your Cookie Settings

We use cookies to enable essential functionality on our website, and analyze website traffic. Read about how we use cookies.

Cookie Categories
Essential

These cookies are strictly necessary to provide you with services available through our websites. You cannot refuse these cookies without impacting how our websites function. You can block or delete them by changing your browser settings, as described under the heading "Managing cookies" in the Privacy and Cookies Policy.

Analytics

These cookies collect information that is used in aggregate form to help us understand how our websites are being used or how effective our marketing campaigns are.